Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC

Introduction: In patients with NSCLC harboring oncogenic ALK or ROS1 rearrangements, tyrosine kinase inhibitors have yielded high response rates and improvements in progression-free survival compared with cytotoxic chemotherapy; however, acquired resistance eventually develops. In preclinical models...

Full description

Bibliographic Details
Main Authors: Matthew S. Lara, BS, Matthew A. Gubens, MD, Bianca Bacaltos, MS, Lea Daran, BA, Steffany L. Lim, BS, Tianhong Li, MD, David R. Gandara, MD, Trever G. Bivona, MD, PhD, Jonathan W. Riess, MD, Collin M. Blakely, MD, PhD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:JTO Clinical and Research Reports
Subjects:
Ceritinib
Trametinib
ALK-rearrangement
ROS1-rearrangment
Non–small cell lung cancer
MEK inhibition
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001606

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001606

Similar Items